Diabetes

Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States

Retrieved on: 
Wednesday, March 27, 2024
FACC, Obesity, Gastroparesis, Metoclopramide, Diabetes, Patient, Volunteering, MD, IND, Nausea, European, Investigational New Drug, Safety, Pharmacokinetics, Phase, Conditional sentence, Vomiting, FDA, Bloating, Pharmaceutical industry

Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.

Key Points: 
  • Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.
  • Renexxion and Dr. Falk Pharma will now expand patient enrollment for the ongoing global multi-center 320 patient placebo-controlled Phase 2b MOVE-IT study in gastroparesis to clinical sites in the United States (ClinicalTrials.gov ID: NCT05621811).
  • Furthermore, naronapride has already demonstrated dose-dependent accelerated gastric emptying in a GI transit study of healthy human volunteers.
  • We are aligned in our belief in the transformative power of naronapride to revolutionize treatment for gastroparesis patients and its ability to reshape the gastroparesis treatment landscape.”

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Blood pressure, Body composition, LDL, Adipose tissue, Obesity, Development, Cirrhosis, Three Months, Exercise, Arrhythmia, Hepatitis B virus, Diabetes, Lipid, Patient, Heart rate, Fast Track, Weight loss, Sarcopenia, MASH, Woman, Diet, Investment, Fibrosis, Safety, Optimism, FDA, Triglyceride, IMPACT, Dietary supplement

“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.

Key Points: 
  • “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
  • “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
  • Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
  • Financial Results for the Three Months Ended December 31, 2023
    Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Retrieved on: 
Tuesday, March 26, 2024
Diabetes, Disease, Echocardiography, HSCS, Congress, Algorithm, Intelligence, Anesthesia, Patient, Mortality, LVDD, Society, Anesthesiology, Type, Use, American Society of Echocardiography, Medical device

Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.

Key Points: 
  • Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
  • In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled.
  • For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
  • Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Tuesday, April 9, 2024
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Development, Risk, Diabetes, Ageing, Chronic obstructive pulmonary disease, Head, RSV, Senior, Asthma, Safety, Vaccine, Person

Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.

Key Points: 
  • Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.
  • However, no RSV vaccines have been approved for use in adults 18 to 59 years of age.
  • The MONeT study was initiated to address this significant unmet need by investigating the immunogenicity and safety of ABRYSVO in adults aged 18 to 59 at increased risk for RSV disease, such as those with asthma, diabetes, and chronic obstructive pulmonary disease.
  • “These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer.

Global Diabetic Footwear Market Research Report 2024: Technological Innovations Propel Demand - Long-term Forecast to 2028 and 2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Retail, Footwear, Diabetes, Health, Growth, Risk, Sale, Quality of life, Shoe, Ageing, Pharmaceutical industry

The "Diabetic Footwear Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Footwear Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • This upward trajectory reflects the escalating demand attributed to the growing global diabetic population and technological innovation within the industry.
  • Several key factors are driving the expansion of the diabetic footwear market.
  • In addition, the rise in e-commerce has significantly enhanced the accessibility and availability of diabetic footwear across various demographics worldwide.

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Deafness, CDMO, Obesity, Syndrome, Infertility, Entrepreneurship, Disease, Diabetes, Ciliopathy, Patient, CRL, DNA, Display resolution, Kidney disease, GMP, Tecmar, Therapy, Paratriathlon, BBS, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .
  • Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
  • Dysfunctional cilia can cause blindness, deafness, chronic respiratory infections, kidney disease, heart disease, infertility, obesity and diabetes.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet the growing demand for plasmid DNA, viral vector, and cell therapy services.

Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024

Retrieved on: 
Tuesday, April 9, 2024
Diabetes, Health, Medical Devices, Webcast, Tandem Diabetes Care, Online shopping

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024.

Key Points: 
  • Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024.
  • The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2024 financial and operating results.
  • A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.
  • An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

United States Cardiovascular Devices Market, Size, Share, Forecast 2024-2030 Featuring Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Cardinal Health, Medtronic, GE, J&J, & Siemens - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Health, Medical Devices, Cardiology, Hospital, Cardiac catheterization, Disease, American Heart Association, Stent, Cardiovascular disease, Coronary artery disease, Prevalence, Biotechnology, CVD, ECG, Incidence, Diabetes, Electrocardiography, Public, Research, Mortality, Insight, Death, Risk, Arrhythmia, Diagnosis, Heart failure, CAD, Medical device

Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.

Key Points: 
  • Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.
  • Technology is pivotal in employing growth in the United States cardiovascular devices market.
  • Numerous market players actively enforce strategic tasks, propelling an increase in the United States cardiovascular devices market.
  • In the United States cardiovascular devices market, diagnostics and monitoring devices have a significant presence
    The United States cardiovascular device market is broken up by device type into Diagnostics and Monitoring Devices and Therapeutic and Surgical Devices.

Global Wearable Technology in Healthcare Market Analysis 2024-2029: AI-powered Medical Wearables and Epidermal Technology Emerging a Key Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Technology, Wearables, Mobile Technology, Momentum, Garmin, Health, Patient, Conditional sentence, Artificial intelligence, Miniaturization, Sennheiser, RPM, Ageing, Lilium, Application, Vital signs, Data analysis, Diabetes, Heart rate, Thermoregulation, Heart failure, Pain management, Polar Electro, Market, Privacy, Medicine, PPG, Blood pressure, Sound, Molina Healthcare, Prevalence, Pharmacy, Computer security, Research, AI, Distribution, Polar, Robotics, Preventive healthcare, Machine learning, Consumer, Temperature, Growth, Remote patient monitoring, Environment, COVID-19, Traction, Government, Rehabilitation, Medical device

The global wearable technology in healthcare market value in 2023 stood at US$42.6 billion, and is likely to reach US$169 billion by 2029.

Key Points: 
  • The global wearable technology in healthcare market value in 2023 stood at US$42.6 billion, and is likely to reach US$169 billion by 2029.
  • The global wearable technology in healthcare market value is projected to grow at a CAGR of 25.82%, during the forecast period of 2024-2029.
  • By Application: According to the report, the global wearable technology in healthcare market is bifurcated into three applications: home healthcare, sports fitness and remote patient monitoring.
  • AI-powered Medical Wearables: Integration of artificial intelligence (AI) in medical wearables enhances data analysis and insights, improving diagnostic accuracy and personalized healthcare delivery.

Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team

Retrieved on: 
Tuesday, April 9, 2024
Data Analytics, General Health, Health, Marketing, Advertising, Communications, Professional Services, Business, Cooking, Growth, Learning, EVP, Disease, Marg, HIV, Steph, Diabetes, Nursing, SVP, KOL, BMS, Evoke, Overalls, Senior, Dog, Creativity, LTC, Multimedia, Tiff, EMT, Management

View the full release here: https://www.businesswire.com/news/home/20240408262170/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240408262170/en/
    Tiffany Marg & Steph Carman (Photo: Business Wire)
    Tiffany has over 20 years of experience in pharmaceutical marketing, building brands and executing campaigns.
  • In her previous role as SVP of Client Services, Tiffany was dedicated to building a first-class service team for Underscore’s clients, ensuring alignment between their ongoing business needs and goals and the execution of Underscore’s strategy and solutions.
  • Tiffany stated, “I am proud of the team we’ve built to lead our client engagements at Underscore and am excited for this next opportunity.
  • I originally came to Underscore because I was passionate about ensuring alignment between clients’ business objectives, brand and creative strategy, and media engagement strategy.